Filippo Alongi1,2, Rosario Mazzola3, Alba Fiorentino1, Stefanie Corradini4, Dario Aiello5, Vanessa Figlia1, Fabiana Gregucci1, Riccardo Ballario6, Stefano Cavalleri6, Ruggero Ruggieri1. 1. Radiation Oncology, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy. 2. University of Brescia, Brescia, Italy. 3. Radiation Oncology, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy. rosariomazzola@hotmail.it. 4. Radiation Oncology, University Hospital, LMU Munich, Munich, Germany. 5. Radiation Oncology School, University of Palermo, Palermo, Italy. 6. Urology, Sacro Cuore Don Calabria Cancer Care Center, Negrar-Verona, Italy.
Abstract
AIM: The goal was to evaluate feasibility, side effects and biochemical no evidence of disease (bNED) after stereotactic body radiation therapy (SBRT) delivered on 5 consecutive days for localized prostate cancer (PC). METHODS: The study was approved by the ethical committee and started in March 2014. Inclusion criteria were age ≤85 years, WHO performance status ≤2, histologically proven adenocarcinoma, low-intermediate risk, no previous surgery (except transurethral resection of the prostate), and a pre-SBRT International Prostatic Symptoms Score of 0-7. The radiotherapy regimen consisted of 35 Gy for low-risk and 37.5 Gy for intermediate-risk PC in 5 consecutive fractions. RESULTS: At the time of the analysis, 52 patients were recruited to the study (median age 73 years, range 55-83 years; median follow-up 34 months, range 12-49 months; 34 patients low-risk and 18 intermediate risk). The median initial prostate-specific antigen (PSA) was 5.9 ng/ml (range 1.8-15.7). Acute genitourinary (GU) toxicity was G0 (grade 0) 36/52 (69%), G1 11/52 (21%), G2 5/52 (10%), while acute rectal (GI) toxicity was G0 43/52 (83%), G1 8/52 (15%), G2 1/52 (2%). No acute toxicity ≥G3 was recorded. At the time of analysis late GU and GI toxicities were as follows: GU-G0 43/52 (83%), GU-G1 7/52 (13%), GU-G2 2/52 (4%); GI-G0 48/52 (92%), GI-G1 2/52 (4%), GI-G2 2/52 (4%). No late toxicities ≥G3 were recorded. bNED was 98%. One patient with intermediate PC had distant progression. CONCLUSIONS: Accelerated SBRT for low-intermediate PC is feasible and well tolerated with comparable oncological outcome as described for other series with the same RT technique but treatment delivery on every other day. Longer follow-up is needed to the assess late toxicity profile and long-term clinical outcome.
AIM: The goal was to evaluate feasibility, side effects and biochemical no evidence of disease (bNED) after stereotactic body radiation therapy (SBRT) delivered on 5 consecutive days for localized prostate cancer (PC). METHODS: The study was approved by the ethical committee and started in March 2014. Inclusion criteria were age ≤85 years, WHO performance status ≤2, histologically proven adenocarcinoma, low-intermediate risk, no previous surgery (except transurethral resection of the prostate), and a pre-SBRT International Prostatic Symptoms Score of 0-7. The radiotherapy regimen consisted of 35 Gy for low-risk and 37.5 Gy for intermediate-risk PC in 5 consecutive fractions. RESULTS: At the time of the analysis, 52 patients were recruited to the study (median age 73 years, range 55-83 years; median follow-up 34 months, range 12-49 months; 34 patients low-risk and 18 intermediate risk). The median initial prostate-specific antigen (PSA) was 5.9 ng/ml (range 1.8-15.7). Acute genitourinary (GU) toxicity was G0 (grade 0) 36/52 (69%), G1 11/52 (21%), G2 5/52 (10%), while acute rectal (GI) toxicity was G0 43/52 (83%), G1 8/52 (15%), G2 1/52 (2%). No acute toxicity ≥G3 was recorded. At the time of analysis late GU and GI toxicities were as follows: GU-G0 43/52 (83%), GU-G1 7/52 (13%), GU-G2 2/52 (4%); GI-G0 48/52 (92%), GI-G1 2/52 (4%), GI-G2 2/52 (4%). No late toxicities ≥G3 were recorded. bNED was 98%. One patient with intermediate PC had distant progression. CONCLUSIONS: Accelerated SBRT for low-intermediate PC is feasible and well tolerated with comparable oncological outcome as described for other series with the same RT technique but treatment delivery on every other day. Longer follow-up is needed to the assess late toxicity profile and long-term clinical outcome.
Authors: Gerhardt Attard; Chris Parker; Ros A Eeles; Fritz Schröder; Scott A Tomlins; Ian Tannock; Charles G Drake; Johann S de Bono Journal: Lancet Date: 2015-06-11 Impact factor: 79.321
Authors: Alan Pollack; Gunar K Zagars; George Starkschall; John A Antolak; J Jack Lee; Eugene Huang; Andrew C von Eschenbach; Deborah A Kuban; Isaac Rosen Journal: Int J Radiat Oncol Biol Phys Date: 2002-08-01 Impact factor: 7.038
Authors: Lindsey A Torre; Rebecca L Siegel; Elizabeth M Ward; Ahmedin Jemal Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-12-14 Impact factor: 4.254
Authors: David P Dearnaley; Gordana Jovic; Isabel Syndikus; Vincent Khoo; Richard A Cowan; John D Graham; Edwin G Aird; David Bottomley; Robert A Huddart; Chakiath C Jose; John H L Matthews; Jeremy L Millar; Claire Murphy; J Martin Russell; Christopher D Scrase; Mahesh K B Parmar; Matthew R Sydes Journal: Lancet Oncol Date: 2014-02-26 Impact factor: 41.316
Authors: Yong Hyun Park; In Young Choi; Sei Chul Yoon; Hong Seok Jang; Hyong Woo Moon; Sung-Hoo Hong; Sae Woong Kim; Tae-Kon Hwang; Ji Youl Lee Journal: Prostate Int Date: 2015-02-12
Authors: Jonathan E Leeman; Daniel N Cagney; Raymond H Mak; Mai Anh Huynh; Shyam K Tanguturi; Lisa Singer; Paul Catalano; Neil E Martin; Anthony V D'Amico; Kent W Mouw; Paul L Nguyen; Martin T King; Zhaohui Han; Christopher Williams; Elizabeth Huynh Journal: Adv Radiat Oncol Date: 2022-03-06
Authors: Thomas Zilli; Sandra Jorcano; Samuel Bral; Carmen Rubio; Anna M E Bruynzeel; Angelo Oliveira; Ufuk Abacioglu; Heikki Minn; Zvi Symon; Raymond Miralbell Journal: Cancer Med Date: 2020-03-11 Impact factor: 4.452
Authors: David J Byun; Daniel J Gorovets; Lauren M Jacobs; Laura Happersett; Pengpeng Zhang; Xin Pei; Sarah Burleson; Zhigang Zhang; Margie Hunt; Sean McBride; Marisa A Kollmeier; Michael J Zelefsky Journal: Radiat Oncol Date: 2020-10-16 Impact factor: 3.481
Authors: Damodar Pokhrel; Tanner Tackett; Joseph Stephen; Justin Visak; Falguni Amin-Zimmerman; Andrew McGregor; Stephen E Strup; William St Clair Journal: J Appl Clin Med Phys Date: 2020-12-19 Impact factor: 2.102